Thus, co-treatment with a combination of three inhibitors for EGFR, MET, and FGFR reduces the tumor size of subcutaneous and intracranial GB xenografts in mice to a greater extent than treatment with two inhibitors for EGFR and MET [20]. The gene discussed is EGFR; the disease is neoplasm.